Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label, Study of Lopinavir/Ritonavir (LPV/r) [Kaletra] Tablets Versus Soft Gel Capsules (SGC) and Once Daily (QD) Versus Twice Daily (BID) Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral Naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects.

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Open-Label, Study of Lopinavir/Ritonavir (LPV/r) [Kaletra] Tablets Versus Soft Gel Capsules (SGC) and Once Daily (QD) Versus Twice Daily (BID) Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral Naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 04 Feb 2012 Additional trial locations added as reported by ClinicalTrials.gov.
    • 01 Aug 2010 Final 96-week efficacy and tolerability results have been published in AIDS Research and Human Retroviruses.
    • 13 Nov 2009 Results with regard to selection of resistance over 96 weeks of therapy have been presented at the 12th European AIDS Conference

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top